Phaseline

Targets › LYN

LYN (Tyrosine-protein kinase Lyn): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology, Metabolic and endocrine; next expected readout Dec 2027.

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. (UniProt, P07948)

Open in Phaseline: the race on LYN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of AlbertaMTX228 (Tolimidone)
Lyn kinase activator
LYNPhase 2Type 1 Diabetes MellitusDec 2027
Baylor College of MedicineBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Children's Oncology GroupBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 1Philadelphia Chromosome Positive CMLJul 2028

Conditions

Chronic Myeloid Leukemia (1) Philadelphia Chromosome Positive CML (1) Type 1 Diabetes Mellitus (1)

Modalities

small molecule (2), other (1)

Companies

Baylor College of Medicine (1) Children's Oncology Group (1) University of Alberta (1)

Related targets

ABL1 (2) SRC (2) HCK (2) BCR (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.